By
Drug Target Review2025-12-12T09:00:13
RNA therapies are moving past burst-and-fade limits. New advances in circular RNA and targeted delivery could transform how we treat autoimmune disease, infections and beyond.
Already a member? Sign in
By highlighting cutting-edge research and its practical applications, Drug Target Review enables readers to make decisions that accelerate innovation, translate discoveries into therapies, and create tangible benefits for patients worldwide.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2026-05-26T09:05:00
Contributor Thomas Clozel M.D., By Drug Target Review
2025-10-08T14:00:00
Sponsored by Eurofins Discovery
2026-06-30T14:00:00 2026-06-30T15:00:00
Sponsored by Analytik Jena GmbH + Co. KG
2024-02-06T08:57:06
Sponsored by bit.bio
2023-01-06T10:25:33
Sponsored by Leica Microsystems
2026-05-22T07:38:00
Contributor Dr Helen Bright, By Drug Target Review
Site powered by Webvision Cloud